RecruitingNCT06161896

Characterization and Clinical Impact of the Gut Microbiota in Lymphoma

Characterization and Clinical Impact of the Gut Microbiota in Diffuse Large B-cell Lymphoma Patients

Sponsor

Lars Møller Pedersen

Enrollment

200 participants

Start Date

May 6, 2024

Study Type

OBSERVATIONAL

Conditions

Diffuse Large B Cell Lymphoma

Summary

The study is a prospective observational single-center cohort study which compare the gut microbiome of newly diagnosed Diffuse Large B-cell Lymphoma patients with the gut microbiome of healthy controls. Furthermore the impact of lymphoma treatment, immune phenotypes, cytokine profiles, metabolomics, inflammation, driver mutations, comorbidity, body composition and lifestyle on the microbiome is also investigated

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study investigates the role of gut bacteria (gut microbiota) in people with rectal cancer. Researchers will analyze bacteria in the gut to understand how they affect cancer behavior, treatment response, and side effects from chemotherapy and radiation. **You may be eligible if...** - You have been diagnosed with rectal cancer - You are scheduled for or receiving neoadjuvant (pre-surgery) chemotherapy and/or radiation - You are 18 or older and willing to provide stool samples **You may NOT be eligible if...** - You have taken antibiotics recently (which alter gut bacteria) - You have had bowel surgery that would affect normal gut bacteria - You have a serious inflammatory bowel disease - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTStool samples

Analysis of microbiome, mutations, alterations in body composition and lifestyle

Locations(1)

Zealand University Hospital, Department of Hematology

Roskilde, Region Sjælland, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06161896

Related Trials

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716128 locations

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

NCT040029471 location

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT032236101 location

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017131 locations

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347258 locations